Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes. (academic.oup.com)

Authors: Pezzati L … Rusconi S Journal: Journal of Antimicrobial Chemotherapy Published: 2026-02-02 DOI: https://doi.org/10.1093/jac/dkag035